Actively Recruiting
The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR
Led by Peking University Third Hospital · Updated on 2024-05-23
200
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to understand the effect of nicotinamide mononucleotide (NMN) on patients with diminished ovarian reserve and the outcomes of IVF/ICSI-ET.
CONDITIONS
Official Title
The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals aged 20 to 40 years
- Meet at least two of the following: anti-Mullerian hormone < 1.1 ng/ml, antral follicle count less than 7, or day-3 follicle-stimulating hormone between 10 IU/L and less than 20 IU/L
- Able to attend continuous outpatient monitoring
- Not participating in other research projects currently or within 3 months before intervention
You will not qualify if you...
- Currently pregnant, breastfeeding, or menopausal
- Have non-46-XX karyotype or known genetic causes
- History of pelvic surgery
- Cancer patients or received chemo/radiotherapy within past 5 years
- Require regular medication for chronic diseases like diabetes, hypertension, gout, or hyperuricemia
- Currently on or had weight-loss drugs or surgery within past 2 months
- Used medications or traditional Chinese medicine affecting hormones, appetite, carbohydrate absorption, or metabolism within past 3 months
- Taken niacin, nicotinamide, vitamin B3-related supplements, coenzyme Q10, or vitamin E currently or within past 3 months
- Used antibiotics, probiotics, or prebiotics affecting flora within past 3 months
- Have severe liver or kidney disease making them ineligible
- History of severe cardiovascular or cerebrovascular disease
- Severe gastrointestinal diseases or gastrointestinal resection affecting nutrient absorption
- Drink more than 15g of alcohol daily or have a smoking habit
- Require drug treatment for mental illness such as epilepsy or depression
- Have infectious diseases like hepatitis B, active tuberculosis, or AIDS
- Unable or unwilling to follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
Research Team
M
Mengyu Liu, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here